使用Player FM应用程序离线!
A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology
Manage episode 428175792 series 3360496
This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.
113集单集
Manage episode 428175792 series 3360496
This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.
113集单集
所有剧集
×



1 9 Million Samples: A New Era of Medicine... Dr. Lincoln Nadauld, President & CEO, Culmination Bio 18:27


1 Reprogramming the Future... Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology 25:51

1 One Drug, Many Diseases??? Dr. David Fajgenbaum, UPenn School of Medicine Professor and President of Every Cure 27:56


1 Fighting Inflammation, and Alzheimer's??? Dr. David Bearss, President & CEO Halia Therapeutics 28:57


1 Data for Good!!!... Sir Rory Collins, Oxford Professor and Principal Investigator, UK Biobank 25:34

1 Building Technology and Solving Problems!!! Dave Pacitti, President & Head of the Americas, Siemens Healthineers 20:30



欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。